share_log

Clovis Oncology Analyst Ratings

Benzinga Analyst Ratings ·  Nov 10, 2022 18:26
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/10/2022 JP Morgan Downgrades Neutral → Underweight
05/06/2022 HC Wainwright & Co. Downgrades Buy → Neutral
05/05/2022 1338.33% HC Wainwright & Co. $5 → $4 Maintains Buy
09/21/2021 3136.25% HC Wainwright & Co. $10 → $9 Maintains Buy
08/05/2021 3495.83% HC Wainwright & Co. $12 → $10 Maintains Buy
05/05/2021 4214.99% HC Wainwright & Co. $13 → $12 Maintains Buy
11/06/2020 978.75% SVB Leerink $4 → $3 Maintains Underperform
11/06/2020 5293.74% HC Wainwright & Co. $23 → $15 Maintains Buy
05/22/2020 10327.9% HC Wainwright & Co. $33 → $29 Reiterates → Buy
05/20/2020 1338.33% SVB Leerink $5 → $4 Maintains Underperform
05/18/2020 11766.24% HC Wainwright & Co. $29 → $33 Maintains Buy
05/06/2020 10327.9% HC Wainwright & Co. $27 → $29 Reiterates → Buy
04/27/2020 1697.91% SVB Leerink → $5 Downgrades Market Perform → Underperform
04/09/2020 2057.5% B of A Securities → $6 Downgrades Neutral → Underperform
01/23/2020 3495.83% B of A Securities $7 → $10 Maintains Neutral
11/19/2019 2776.66% Evercore ISI Group → $8 Downgrades Outperform → In-Line
10/08/2019 978.75% Goldman Sachs $13 → $3 Maintains Sell
09/24/2019 SVB Leerink Downgrades Outperform → Market Perform
08/13/2019 2417.08% B of A Securities $13 → $7 Downgrades Buy → Neutral
08/02/2019 Guggenheim Downgrades Buy → Neutral
05/29/2019 5293.74% Goldman Sachs $17 → $15 Downgrades Neutral → Sell
02/13/2019 14283.32% HC Wainwright & Co. → $40 Initiates Coverage On → Buy
10/31/2018 14283.32% Barclays $58 → $40 Maintains Overweight
10/31/2018 5653.33% JP Morgan $71 → $16 Downgrades Overweight → Neutral
09/25/2018 10687.49% Leerink Swann → $30 Initiates Coverage On → Market Perform
02/27/2018 30464.55% Barclays $105 → $85 Maintains Overweight
02/27/2018 39454.12% Stifel $125 → $110 Maintains Buy
02/22/2018 Evercore ISI Group Upgrades In-Line → Outperform
02/22/2018 RBC Capital Upgrades Sector Perform → Outperform

What is the target price for Clovis Oncology (CLVS)?

The latest price target for Clovis Oncology (NASDAQ: CLVS) was reported by JP Morgan on November 10, 2022. The analyst firm set a price target for $0.00 expecting CLVS to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Clovis Oncology (CLVS)?

The latest analyst rating for Clovis Oncology (NASDAQ: CLVS) was provided by JP Morgan, and Clovis Oncology downgraded their underweight rating.

When is the next analyst rating going to be posted or updated for Clovis Oncology (CLVS)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Clovis Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Clovis Oncology was filed on November 10, 2022 so you should expect the next rating to be made available sometime around November 10, 2023.

Is the Analyst Rating Clovis Oncology (CLVS) correct?

While ratings are subjective and will change, the latest Clovis Oncology (CLVS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Clovis Oncology (CLVS) is trading at is $0.28, which is out of the analyst's predicted range.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment